Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific production - Institute for Cancer Research
Important findings from Skjeven, Lødrup Carlsen and coworkers published in New England Journal of Medicine
Håvard Ove Skjerven and Karin C. Lødrup Carlsen (photo) from the Department of Pediatrics at OUS are first and last author of an article published in New England Journal of Medicine (journal impact factor 53.3) June 13th, entitled "Racemic Adrenaline and Inhalation Strategies in Acute Bronchiolitis". In this paper Skjerven, Lødrup Carlsen and coworkers aimed to assess the effectiveness of inhaled racemic adrenaline as compared with inhaled saline and the strategy for frequency of inhalation (on demand vs. fixed schedule) in infants hospitalized with acute bronchiolitis. Their findings has led to changes in the national guidelines, thus improving the treatment of bronchiolits.
Helse Sør-Øst RHF, in cooperation with the University of Oslo, are now announcing research funding opportunities for 2014.
The application deadline is 6th September 2013, 4:00 PM.
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".
For the month of May 2013, this honor goes to Guttorm Haraldsen from the Department of Pathology at the Division of Diagnostics and Intervention at Oslo University Hospital.
Anja Nilsen (photo) from Arne Klungland's group at the Department of Microbiology, Oslo University Hospital, is shared first-author on a collaborative work entitled "ALKBH4-dependent demethylation of actin regulates actomyosin dynamics", recently published in Nature communications.
Rolf Skotheim (photo) is the site responsible in Oslo, and says that across all types of cancer, testicular cancer is now the type for which known susceptibility genes explain the largest fraction the genetic risk.
A kick-off seminar focusing on how to improve recruitment and facilitate career building within the field of health research will be held in the new research building at the Norwegian Radium Hospital at Montebello June 21st. Main target groups for the seminar are leaders and heads of research from hospital trusts, universities and colleges within South-Eastern Norway Regional Health Authority (Helse Sør-Øst). The programs represent a regional effort from Helse Sør-Øst.
Jun 17, 2013
Jun 14, 2013
International approaches to personalized cancer medicine
Jun 5, 2013
Inst. for Cancer Research
Exosome-Derived miRNAs and Cellular miRNAs Activate Innate Immunity
J Innate Immun (in press)
Retrograde transport of protein toxins through the Golgi apparatus
Histochem Cell Biol (in press)
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
High-Purity Hydrogen via the Sorption-Enhanced Steam Methane Reforming Reaction over a Synthetic CaO-Based Sorbent and a Ni Catalyst
Environ Sci Technol, 47 (11), 6007-14
Influence of KIR gene copy number on natural killer cell education
Blood, 121 (23), 4703-7